OFW
NBIX icon

Omnia Family Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Omnia Family Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-36
Closed -$3K – 370
2019
Q1 		$3K Hold
36
– – ﹤0.01% 403
2018
Q4 		$3K Hold
36
– – ﹤0.01% 348
2018
Q3 		$4K Hold
36
– – ﹤0.01% 332
2018
Q2 		$4K Hold
36
– – ﹤0.01% 326
2018
Q1 		$3K Hold
36
– – ﹤0.01% 372
2017
Q4 		$3K Hold
36
– – ﹤0.01% 379
2017
Q3 		$2K Buy
+36
New +$1.9K ﹤0.01% 484
2017
Q1 		– Sell
-23
Closed -$1K – 756
2016
Q4 		$1K Buy
+23
New +$1.04K ﹤0.01% 696

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Omnia Family Wealth's NBIX Position: Q2 2019 in Review

Omnia Family Wealth sold out of Neurocrine Biosciences (NBIX) in Q2 2019, closing a stake of 36 shares — an estimated $3K sold.

Omnia Family Wealth first reported a position in NBIX in Q4 2016 and held it in 8 quarters. The position peaked at $4K in Q3 2018. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

  • Omnia Family Wealth reported no remaining Neurocrine Biosciences position as of Q2 2019 after selling out during the quarter.
  • Omnia Family Wealth sold 36 Neurocrine Biosciences shares in Q2 2019, an estimated $3K.
  • Omnia Family Wealth first reported a position in Neurocrine Biosciences in Q4 2016 and held it in 8 quarters.
  • Omnia Family Wealth's Neurocrine Biosciences position peaked at $4K in Q3 2018.
  • 302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on Omnia Family Wealth's 13F filing for Q2 2019, filed 7 Aug 2019.